These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Virgin Media O2 has deployed what it claims to be the UK's first 5G Standalone (5G SA) small cells. In an announcement today ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and ...

Against a backdrop of rising demand, with the amount of mobile data consumed by its mobile communications customers having been measured to have increased by 26% in 2023, Virgin Media O2 (VMO2) has ...

For the past decade, scientists have relied almost exclusively on CRISPR-Cas systems for genome editing. Now, a smaller but ...

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.

After launching their commercial 5G Standalone (SA) mobile network during February 2024 (here), O2 (Virgin Media) has today ...